Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
7 | 4 | CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL | 1572904 |
301 | 3 | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY//LEVOSIMENDAN//PHARMACOLOGY & PHARMACY | 41522 |
980 | 2 | NICORANDIL//CALCIUM ANTAGONISTS//CALCIUM CHANNEL BLOCKERS | 10891 |
1503 | 2 | NEBIVOLOL//CARVEDILOL//BETA BLOCKERS | 7786 |
1844 | 2 | ALPHA1 ADRENOCEPTOR SUBTYPE//ALPHA1 ADRENOCEPTOR//CHLOROETHYLCLONIDINE | 6467 |
2347 | 2 | I 123 MIBG//IODINE 123 METAIODOBENZYLGUANIDINE//METAIODOBENZYLGUANIDINE | 4640 |
2598 | 2 | LEVOSIMENDAN//CALCIUM SENSITIZER//MILRINONE | 3876 |
2675 | 2 | RENALASE//HEART KIDNEY//IBOPAMINE | 3657 |
2779 | 2 | NITRATE TOLERANCE//NITROGLYCERIN//ORGANIC NITRATES | 3362 |
3965 | 2 | DIHYDRALAZINE SULFATE//TRIMELAMOL//HYDRALAZINE | 843 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | journal | 281800 | 5% | 19% | 2033 |
2 | LEVOSIMENDAN | authKW | 257792 | 1% | 85% | 401 |
3 | PHARMACOLOGY & PHARMACY | WoSSC | 205765 | 41% | 2% | 17214 |
4 | CARDIAC & CARDIOVASCULAR SYSTEM | WoSSC | 144199 | 24% | 2% | 9883 |
5 | NICORANDIL | authKW | 126080 | 1% | 58% | 290 |
6 | CALCIUM ANTAGONISTS | authKW | 119676 | 1% | 31% | 513 |
7 | NEBIVOLOL | authKW | 109603 | 1% | 63% | 231 |
8 | CARVEDILOL | authKW | 103062 | 1% | 38% | 364 |
9 | ALPHA1 ADRENOCEPTOR SUBTYPE | authKW | 81353 | 0% | 79% | 136 |
10 | NITRATE TOLERANCE | authKW | 80302 | 0% | 76% | 139 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 205765 | 41% | 2% | 17214 |
2 | Cardiac & Cardiovascular System | 144199 | 24% | 2% | 9883 |
3 | Peripheral Vascular Diseases | 32922 | 9% | 1% | 3685 |
4 | Medicine, General & Internal | 10145 | 9% | 1% | 3646 |
5 | Chemistry, Medicinal | 6171 | 4% | 1% | 1812 |
6 | Physiology | 5302 | 5% | 1% | 2016 |
7 | Medicine, Research & Experimental | 3453 | 5% | 0% | 1926 |
8 | Toxicology | 1405 | 3% | 0% | 1059 |
9 | Chemistry, Analytical | 1361 | 4% | 0% | 1689 |
10 | Anesthesiology | 746 | 1% | 0% | 481 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | HEART KIDNEY | 27103 | 0% | 73% | 49 |
2 | EUROPEAN HLTH INEQUAL OBSERV | 8526 | 0% | 87% | 13 |
3 | CARDIAC PHYSIOL | 7525 | 0% | 19% | 54 |
4 | BIOCHEM BIOINFORMAT SCI | 7390 | 0% | 43% | 23 |
5 | CARDIOVASC STUDIES | 7173 | 0% | 50% | 19 |
6 | CARDIOL | 6887 | 3% | 1% | 1423 |
7 | MED BIOL SCI CARDIOVASC MED | 6101 | 0% | 73% | 11 |
8 | ORGAN CHEM CPC 2 | 4812 | 0% | 58% | 11 |
9 | CRIT CARE PROPRIETARY PROD | 4542 | 0% | 100% | 6 |
10 | HLTH PROMOT FOOD NUTR | 4153 | 0% | 50% | 11 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | 281800 | 5% | 19% | 2033 |
2 | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 50980 | 2% | 10% | 701 |
3 | JOURNAL OF AUTONOMIC PHARMACOLOGY | 50771 | 1% | 28% | 238 |
4 | NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 49226 | 2% | 10% | 637 |
5 | BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 43631 | 2% | 9% | 697 |
6 | CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 41155 | 1% | 11% | 515 |
7 | CARDIOVASCULAR DRUGS AND THERAPY | 37000 | 1% | 16% | 312 |
8 | AMERICAN JOURNAL OF CARDIOLOGY | 33073 | 3% | 4% | 1112 |
9 | BRITISH JOURNAL OF PHARMACOLOGY | 29239 | 2% | 5% | 850 |
10 | ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH | 28246 | 1% | 10% | 400 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | LEVOSIMENDAN | 257792 | 1% | 85% | 401 | Search LEVOSIMENDAN | Search LEVOSIMENDAN |
2 | NICORANDIL | 126080 | 1% | 58% | 290 | Search NICORANDIL | Search NICORANDIL |
3 | CALCIUM ANTAGONISTS | 119676 | 1% | 31% | 513 | Search CALCIUM+ANTAGONISTS | Search CALCIUM+ANTAGONISTS |
4 | NEBIVOLOL | 109603 | 1% | 63% | 231 | Search NEBIVOLOL | Search NEBIVOLOL |
5 | CARVEDILOL | 103062 | 1% | 38% | 364 | Search CARVEDILOL | Search CARVEDILOL |
6 | ALPHA1 ADRENOCEPTOR SUBTYPE | 81353 | 0% | 79% | 136 | Search ALPHA1+ADRENOCEPTOR+SUBTYPE | Search ALPHA1+ADRENOCEPTOR+SUBTYPE |
7 | NITRATE TOLERANCE | 80302 | 0% | 76% | 139 | Search NITRATE+TOLERANCE | Search NITRATE+TOLERANCE |
8 | ALPHA1 ADRENOCEPTOR | 79073 | 1% | 38% | 279 | Search ALPHA1+ADRENOCEPTOR | Search ALPHA1+ADRENOCEPTOR |
9 | BETA BLOCKERS | 69762 | 1% | 17% | 556 | Search BETA+BLOCKERS | Search BETA+BLOCKERS |
10 | CALCIUM CHANNEL BLOCKERS | 66044 | 1% | 19% | 461 | Search CALCIUM+CHANNEL+BLOCKERS | Search CALCIUM+CHANNEL+BLOCKERS |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 3 |